Cardiology Division, San Luca Hospital, Lucca, Italy.
CNR Institute of Clinical Physiology, Pisa, Italy.
Am J Cardiol. 2019 Sep 15;124(6):972-977. doi: 10.1016/j.amjcard.2019.06.017. Epub 2019 Jun 26.
A blunted heart rate (HR) response during dipyridamole myocardial perfusion imaging has been associated with a poor outcome. To assess the value of HR response in patients who underwent high-dose dipyridamole stress echocardiography (SE), we retrospectively selected a sample of 3,059 patients (none with pacemakers or atrial fibrillation; mean age 66 ± 11 years). All underwent high-dose (0.84 mg/kg) dipyridamole SE for evaluation of known or suspected coronary artery disease and/or heart failure in 2 laboratories of Pisa-IFC and Lucca. HR (with 12-lead ECG) was obtained each minute and recorded at rest and peak stress. HR reserve (HRR) was calculated as the peak/rest HR ratio. All patients were followed up. Patients were randomly divided into the modeling and validation group of equal size. During a median follow-up time of 1,004 days, 321 hard events occurred: 231 deaths and 90 nonfatal myocardial infarctions. HRR ≤ 1.22 identified by receiver operating characteristic analysis in the modeling group was an independent predictor of infarction-free survival in the modeling (hazard ratio 1.83, 95% confidence interval [CI] 1.30 to 2.60, p = 0.001), in the validation (hazard ratio 1.47, 95% CI 1.08 to 2.01, p = 0.02), and in the overall group (hazard ratio 1.60, 95% CI 1.27 to 2.02, p <0.0001), either off- or on-β blockers. Five-year event rate increased from 8% to 24 % from the highest (≥1.41) to the lowest (≤1.14) HRR quartile. In conclusion, blunted HRR is a useful nonimaging predictor of adverse events during high-dose dipyridamole SE, independent of inducible ischemia, and beta-blocker therapy.
在双嘧达莫心肌灌注成像中,心率(HR)反应迟钝与预后不良有关。为了评估在接受大剂量双嘧达莫负荷超声心动图(SE)的患者中 HR 反应的价值,我们回顾性选择了 3059 例患者(均无起搏器或心房颤动;平均年龄 66±11 岁)的样本。所有患者均在比萨-IFC 和卢卡的 2 个实验室接受大剂量(0.84mg/kg)双嘧达莫 SE 检查,用于评估已知或疑似冠心病和/或心力衰竭。HR(通过 12 导联心电图获得)在静息和峰值应激时每分钟记录一次,并记录下来。HR 储备(HRR)计算为峰值/静息 HR 比值。所有患者均接受随访。患者被随机分为建模组和验证组,每组大小相等。在中位数为 1004 天的随访期间,发生 321 例硬终点事件:231 例死亡和 90 例非致死性心肌梗死。在建模组中,通过受试者工作特征分析确定的 HRR≤1.22 是建模组(危险比 1.83,95%置信区间 [CI] 1.30 至 2.60,p=0.001)、验证组(危险比 1.47,95%CI 1.08 至 2.01,p=0.02)和总体组(危险比 1.60,95%CI 1.27 至 2.02,p<0.0001)中无梗死生存率的独立预测因子,无论是否使用β受体阻滞剂。从最高(≥1.41)到最低(≤1.14)HRR 四分位数,5 年事件发生率从 8%增加到 24%。总之,在大剂量双嘧达莫 SE 期间,HRR 迟钝是不良事件的有用非影像预测因子,独立于可诱导缺血和β受体阻滞剂治疗。